{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Rhesus macaques in an Oregon research center are being turned into couch potatoes with weight problems for study.", "headline": {"seo": "Monkeys Fattened Up to Study Human Obesity", "main": "Today\u2019s Lab Rats of Obesity: Furry Couch Potatoes", "print_headline": "Today\u2019s Lab Rats of Obesity: Furry, Fattened Couch Potatoes"}, "abstract": null, "print_page": "1", "word_count": "1462", "_id": "540af9ea7988101836d977e5", "snippet": "Rhesus macaques in an Oregon research center are being turned into couch potatoes with weight problems for study.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2011/02/20/health/20monkey.html", "multimedia": [{"subtype": "thumbnail", "url": "images/2011/02/20/business/Monkey/Monkey-thumbStandard-v3.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2011/02/20/business/Monkey/Monkey-thumbStandard-v3.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Obesity", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Research", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Monkeys and Apes", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Diabetes", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "People for the Ethical Treatment of Animals", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Animals", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "7", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2011-02-20T00:00:00Z", "section_name": "Health"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "Do drugs for attention deficit hyperactivity disorder need to be taken for life? Are they dangerous? Are there alternatives to medications? There are among the questions posed by readers of the Consults blog. Dr. Russell A. Barkley, clinical professor of psychiatry at the Medical University of South Carolina and author, most recently, of \"Taking Charge of Adult A.D.H.D.,\" responds.", "headline": {"main": "A.D.H.D.: To Medicate or Not to Medicate?", "kicker": "Consults"}, "abstract": "Dr. Russell Barkley responds to reader questions about attention-deficit hyperactivity disorder.", "print_page": null, "word_count": 1387, "_id": "4fd39e5e8eb7c8105d8e103f", "snippet": "Dr. Russell Barkley responds to reader questions about attention-deficit hyperactivity disorder.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://consults.blogs.nytimes.com/2011/02/17/a-d-h-d-to-medicate-or-not-to-medicate/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Medicine and Health", "name": "subject", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3"}, {"value": "Attention Deficit Hyperactivity Disorder", "name": "subject", "rank": "2"}, {"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"organization": "THE NEW YORK TIMES", "original": "By THE NEW YORK TIMES", "person": []}, "document_type": "blogpost", "pub_date": "2011-02-17T15:15:42Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "7:16 p.m. | Updated PARIS - The French drug maker Sanofi-Aventis said on Wednesday that it had agreed to buy the American biotechnology company Genzyme for at least $20.1 billion in cash, with additional payments possible based on the performance of Genzyme's drugs.", "headline": {"main": "French Drug Maker to Buy Genzyme for $20.1 Billion"}, "abstract": "Sanofi-Aventis agrees to buy Genzyme for at least $20.1 billion in cash, with additional payments possible based on the performance of Genzyme's drugs (M)", "print_page": "10", "word_count": 749, "_id": "4fd2ab0e8eb7c8105d89784f", "snippet": "7:16 p.m. | Updated      PARIS - The French drug maker Sanofi-Aventis said on Wednesday that it had agreed to buy the American biotechnology company Genzyme for at least $20.1 billion in cash, with additional payments possible based on the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9E03E3DD103DF934A25751C0A9679D8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "GENZYME CORP"}, {"name": "organizations", "value": "SANOFI-AVENTIS"}, {"name": "subject", "value": "MERGERS, ACQUISITIONS AND DIVESTITURES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}], "byline": {"person": [{"firstname": "Chris", "middlename": "V.", "lastname": "NICHOLSON", "rank": 1, "role": "reported", "organization": ""}], "original": "By CHRIS V. NICHOLSON"}, "document_type": "article", "pub_date": "2011-02-17T00:00:00Z", "section_name": "Business"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "7:16 p.m. | Updated", "headline": {"main": "Sanofi Agrees to Buy Genzyme for $20.1 Billion", "kicker": "DealBook"}, "abstract": "The deal ends months of haggling after Sanofi-Aventis unsuccessfully sought to acquire Genzyme for $18.5 billion.", "print_page": null, "word_count": 717, "_id": "4fd39ec78eb7c8105d8e1e3a", "snippet": "The deal ends months of haggling after Sanofi-Aventis unsuccessfully sought to acquire Genzyme for $18.5 billion.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://dealbook.nytimes.com/2011/02/16/sanofi-agrees-to-buy-genzyme-for-at-least-20-1-billion/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3"}, {"value": "Viehbacher, Christopher A", "name": "persons", "rank": "2"}, {"value": "Genzyme Corp", "name": "organizations", "rank": "5"}, {"value": "News", "name": "type_of_material", "rank": "1"}, {"value": "Sanofi-Aventis S.A", "name": "organizations", "rank": "6"}, {"value": "Genzyme Corp|GENZ|NASDAQ", "name": "unknown", "rank": "7"}, {"value": "Sanofi-Aventis S.A|SNY|NYSE", "name": "unknown", "rank": "8"}], "byline": {"person": [{"firstname": "Chris", "middlename": "V.", "lastname": "NICHOLSON", "rank": 1, "role": "reported", "organization": ""}], "original": "By CHRIS V. NICHOLSON"}, "document_type": "blogpost", "pub_date": "2011-02-16T03:00:19Z", "section_name": "Business Day"}, {"type_of_material": "Editorial", "blog": [], "news_desk": "Editorial", "lead_paragraph": "Time for a reality check on Republicans\u2019 criticism of temporary high-risk insurance pools, set up as part of health care reform.", "headline": {"seo": "The Skirmish Over High-Risk Pools", "main": "The Skirmish Over High-Risk Pools", "kicker": "Editorial", "print_headline": "The Skirmish Over High-Risk Pools", "content_kicker": "Editorial"}, "abstract": null, "print_page": "24", "word_count": "444", "_id": "540ad56c7988101836d97549", "snippet": "Time for a reality check on Republicans\u2019 criticism of temporary high-risk insurance pools, set up as part of health care reform.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2011/02/16/opinion/16wed3.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Reform and Reorganization", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Health Insurance and Managed Care", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Patient Protection and Affordable Care Act (2010)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Republican Party", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "House of Representatives", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Senate", "is_major": "N", "rank": "6", "name": "organizations"}], "byline": [], "document_type": "article", "pub_date": "2011-02-16T00:00:00Z", "section_name": "Opinion"}], "meta": {"hits": 5, "offset": 0, "time": 59}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}